Skip to content

The China CardioMyopathy Registry Study

The China CardioMyopathy Registry Study

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05871632
Acronym
CHINA-CM
Enrollment
5000
Registered
2023-05-23
Start date
2023-07-01
Completion date
2027-06-30
Last updated
2023-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiomyopathies

Brief summary

Cardiomyopathy is the most common inherited cardiovascular disease, showing family aggregation, so it has a huge psychological and economic burden on family members. Studying the clinical characteristics of patients with cardiomyopathy is helpful for further diagnosis, treatment and management, which has important clinical and social significance.

Detailed description

In this study, patients hospitalized with cardiomyopathy as the primary discharge diagnosis in China are recruited prospectively after informed consent was given. The investigator will collect the baseline clinical characteristics of the patients at enrollment, including comprehensive physical examination, laboratory testing of blood and urine, electrocardiography, 24-hour Holter, echocardiography, MRI and other examinations if necessary. Data are collected with the use of case report forms (CRFs) and are entered into a web-based system. A 6 mL venous blood sample is obtained from consenting patients. Each participant is scheduled to be followed up by telephone every 12 months after admission to hospital.

Interventions

None listed

Sponsors

China National Center for Cardiovascular Diseases
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with primary discharge diagnosis meeting one of the following subtypes of cardiomyopathy were enrolled, including HCM, DCM, ACM, RCM, left ventricular non-compaction, cardiac amyloidosis, Fabry disease, Pompe disease, Danon disease, and PRKAG2 cardiac syndrome.

Exclusion criteria

* Patients who refuse to sign the informed consent or decline follow-up.

Design outcomes

Primary

MeasureTime frameDescription
number of participants with cardiovascular deathsan average of 1 yearincluding sudden cardiac death and deaths due to heart failure and stroke

Secondary

MeasureTime frameDescription
number of participants with heart failurean average of 1 yearprogress to level III or IV in New York Heart Association class
number of participants with strokean average of 1 yearincluding cerebral infraction and hemorrhage
number of participants with myocardial infarctionan average of 1 yearincluding ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction
number of participants with all-cause deathsan average of 1 yearincluding deaths due to any causes

Countries

China

Contacts

Primary ContactLei Song, MD.&phD
clinicalfw@163.com86-13810532620

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026